Immunitas Therapeutics has reached $97m of total funding after announcing the close of its series B round featuring more than half a dozen corporates.
US-based immuno-oncology therapy developer Immunitas Therapeutics has raised $58m in a series B round featuring corporates Bayer, Alexandria Real Estate Equities, Novartis, Dong-A ST, Merck Group, Ono Pharmaceutical and Evotec.
Venture capital firm Agent Capital led the round, in which pharmaceutical firms Novartis, Ono Pharmaceutical, Merck Group and Dong-A ST participated through Novartis Venture Fund, Ono Venture Investment, M Ventures and NS Investment, respectively.
Pharmaceutical and chemical group Bayer’s Leaps by Bayer unit also took part, while Alexandria Venture Investments…
